Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies
-
- Jan Heyckendorf
- Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany
-
- Sophia B. Georghiou
- FIND, the Global Alliance for Diagnostics, Geneva, Switzerland
-
- Nicole Frahm
- Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA
-
- Norbert Heinrich
- Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany
-
- Irina Kontsevaya
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
-
- Maja Reimann
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
-
- David Holtzman
- FIND, the Global Alliance for Diagnostics, Geneva, Switzerland
-
- Marjorie Imperial
- University of California San Francisco, San Francisco, California, USA, United States
-
- Daniela M. Cirillo
- Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
-
- Stephen H. Gillespie
- School of Medicine, University of St Andrews, St Andrews, Fife, Scotland
-
- Morten Ruhwald
- FIND, the Global Alliance for Diagnostics, Geneva, Switzerland
抄録
<jats:p>Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success.</jats:p>
収録刊行物
-
- Clinical Microbiology Reviews
-
Clinical Microbiology Reviews 35 (3), 2022-09-21
American Society for Microbiology